Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients
Coronavirus disease 2019 (COVID-19) caused a progress in research to find a solution to this pandemic. Also, various advances in pharmacotherapy against COVID-19 have emerged. Regarding antiviral therapy, casirivimab and imdevimab are antibodies combination against COVID-19. Standard antiviral thera...
| Автори: | , , |
|---|---|
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
De Gruyter
2023-08-01
|
| Серія: | Open Medicine |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1515/med-2023-0768 |